Compare Heron Therapeutics Inc (HRTX) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Target Corporation — how do they compare? Heron Therapeutics Inc trades at $0.38 (market cap $68.01M), while Target Corporation trades at $153.09 (market cap $70.31B). The key difference: Target Corporation is far larger — about 1033.8× Heron Therapeutics Inc's market cap, and Target Corporation pays a 3% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Target Corporation for 137 Days on average.
| HRTX | TGT | |
|---|---|---|
Market Cap | $68.01M | $70.31B |
Volume | 1,891,941 | 4,164,999 |
Sector | Health | Consumer Staples |
52-Week High | $1.49 | $169.90 |
52-Week Low | $0.27 | $83.68 |
Typical Hold Time | 35 Days | 137 Days |
Enterprise Value | $174.75M | $83.58B |
Dividend Yield | — | 3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
Target trades at $150.96, down 2.18% today, with technical indicators showing bearish momentum. The company maintains solid fundamentals with a P/E of 16.05 and strong profitability metrics including 26.41% ROE. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $4.11 significantly exceeding the $2.35 forecast. The company's holiday price-cutting strategy aims to capture market share amid competitive retail pressures.
Target presents a mixed outlook with 46.7% analyst buy ratings and a $167.18 consensus target suggesting 10.8% upside. Strong cash flow generation and dividend sustainability support the investment case, though margin pressures from aggressive pricing and retail competition pose near-term challenges. The stock's current valuation appears reasonable relative to historical levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
